ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO472

High Urinary Sodium Is Not Always SIADH

Session Information

Category: Fluid‚ Electrolyte‚ and Acid-Base Disorders

  • 1002 Fluid‚ Electrolyte‚ and Acid-Base Disorders: Clinical

Authors

  • Amin, Sahar, The University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, United States
  • Mettupalli, Neeharika, The University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, United States
  • Chedid, Alice, The University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, United States
Introduction

Cisplatin nephrotoxicity has been well described in the literature. However, renal salt wasting (RSW) is relatively uncommon. We present an interesting case of severe hyponatremia secondary to Cisplatin that mimicked SIADH but improved with administration of IV fluids.

Case Description

A 39-year-old AA male with newly diagnosed small cell lung cancer was admitted for induction chemotherapy. Initial physical exam was unremarkable. Vital signs were normal, BP 120/77 mm Hg and HR 85. Laboratory: Na 132 mEq/l with normal creatinine at 0.6 mg/dl. Patient was given Cisplatin 80mg/m2 x1. Day 2, Na at 128 meq/l. Day 3, Na droped to 123 meq/l. Further workup: Serum osm 246 mOsm, TSH and cortisol WNL. MRI negative for brain metastases. Urine osmolarity at 726 mOsm with urine sodium of 222 mEq/l. Given malignancy concern, patient was treated as SIADH with fluid restriction. Na continued to drop, down to 117 meq/l (graph below). Upon rechecking vitals, patient was orthostatic and was complaining of dizziness. Given hypovolemia, RSW 2/2 cisplatin was suspected. Patient was started on NS infusion with slow and gradual improvement of his serum Na to normal. NS was eventually stopped, and patient was transitioned to salt tablets. Patient was not rechallenged with cisplatin.

Graph 1: Sodium Trend

Discussion

Renal salt wasting is a rare side effect of Cisplatin that manifests as hypovolemic hyponatremia. Given the clinical and laboratory similarities, it is often misdiagnosed as SIADH. We want to shed light on the importance of recognizing this entity because restoration of intravascular volume is of the essence.